The proceeds will also be used to fund Remepy’s lead product Hybridopa’s global Phase III clinical trial targeting Parkinson’s disease (PD). It is set to commence in the fourth quarter of 2026.
The latest funding brings the total capital raised by the company to $62m.
The Series A round was led by OG Venture Partners and M Ventures, Merck KGaA, Darmstadt, Germany’s corporate strategic venture arm.
Other new and existing backers include NFX, Qumra Capital, Tadmor Group, TechAviv, and Vine Ventures.
Remepy develops Hybrid Drugs through partnerships with pharmaceutical companies.
These drugs combine prescription medicines with personalised, AI-driven therapeutic applications, aiming to integrate pharmacology with adaptive physical, cognitive, and behavioural interventions into a single treatment regimen.
The company stated that the Hybrid Drug model has gained traction, supported by evolving US regulatory frameworks for drug-software combination products.
Remepy recently disclosed a strategic partnership with Merck KGaA, Darmstadt, Germany to develop hybrid drugs for multiple indications, beginning with rare tumours.
Hybridopa, it’s lead programme for Parkinson’s disease, has reported positive Phase IIa clinical data regarding both motor and non-motor symptom improvement.
It remains an investigational product and has not received approval from the US Food and Drug Administration.
Remepy co-CEOs Michal Tsur and Or Shoval said: “We believe medicine is entering a new era, where every breakthrough drug will be paired with personalised intelligence to maximise its impact for every patient.
“Over the past year, we’ve demonstrated that this vision is achievable through clinical validation, peer-reviewed science, regulatory alignment, and partnerships with leading pharmaceutical companies.
“This financing allows us to advance Phase III of Hybridopa for Parkinson’s disease, and expand the hybrid drug model across multiple therapeutic areas.”